MCM
RARE icon

MAI Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

MAI Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Buy
14,846
+5,962
+67% +$148K ﹤0.01% 1306
2026
Q1 		$186K Buy
+8,884
New +$200K ﹤0.01% 1503
2025
Q4 		– Sell
-47
Closed -$1.41K – 4462
2025
Q3 		$1.41K Sell
47
-153
-77% -$4.59K ﹤0.01% 3397
2025
Q2 		$7.27K Buy
200
+147
+277% +$5.3K ﹤0.01% 2886
2025
Q1 		$1.92K Hold
53
– – ﹤0.01% 2981
2024
Q4 		$2.23K Buy
+53
New +$2.63K ﹤0.01% 3009

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

MAI Capital Management's RARE Position: Q2 2026 in Review

MAI Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 67% in Q2 2026, buying an estimated $148K and bringing the position to 14,846 shares worth $496K. The position accounts for ﹤0.01% of the portfolio, ranked #1306.

MAI Capital Management first reported a position in RARE in Q4 2024 and has held it in 6 quarters since. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • MAI Capital Management held 14,846 shares of Ultragenyx Pharmaceutical worth $496K as of Q2 2026.
  • MAI Capital Management bought 5,962 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $148K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of MAI Capital Management's portfolio in Q2 2026, its #1306 holding.
  • MAI Capital Management first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and has held it in 6 quarters since.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on MAI Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.